Ignite Creation Date:
2024-05-06 @ 4:24 PM
Last Modification Date:
2024-10-26 @ 2:09 PM
Study NCT ID:
NCT04976634
Status:
RECRUITING
Last Update Posted:
2024-06-27
First Post:
2021-07-16
Brief Title:
Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Solid Tumors MK-6482-016
Sponsor:
Merck Sharp Dohme LLC
Organization:
Merck Sharp Dohme LLC
Conditions & Keywords Data
Conditions:
| Name |
|---|
| Esophageal Neoplasms |
| Carcinoma Hepatocellular |
| Colorectal Neoplasms |
| Pancreatic Ductal Adenocarcinoma |
| Biliary Tract Neoplasms |
| Endometrial Neoplasms |
Keywords: